Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 17/20 | 0.48 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6692447 | 1.00 | CTSC (0.48) | CTSCBACE1CTSLCTSSMEN1 | |
| SCHEMBL6630423 | 1.00 | CTSC (0.48) | CTSCBACE1CTSLCTSSMEN1 | |
| SCHEMBL6653200 | 0.86 | BACE1 (0.38) | CTSCBACE1MEN1ALDH1A1CYP1A2 | |
| SCHEMBL6628301 | 0.86 | BACE1 (0.38) | CTSCBACE1MEN1ALDH1A1CYP1A2 | |
| SCHEMBL6653196 | 0.86 | BACE1 (0.38) | CTSCBACE1MEN1ALDH1A1CYP1A2 | |
| SCHEMBL6655217 | 0.86 | BACE1 (0.38) | CTSCBACE1MEN1ALDH1A1CYP1A2 | |
| SCHEMBL5526913 | 0.84 | NPC1 (0.37) | ALDH1A1KMT2A | |
| SCHEMBL6062966 | 0.83 | CTSK (0.51) | BACE1CTSLCTSS | |
| SCHEMBL6062962 | 0.83 | CTSK (0.51) | BACE1CTSLCTSS | |
| SCHEMBL6062971 | 0.83 | CTSK (0.51) | BACE1CTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | CTSC 13/4885BACE1 53/4885CTSL 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.